Texas Permanent School Fund Corp cut its position in West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) by 2.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,262 shares of the medical instruments supplier’s stock after selling 307 shares during the period. Texas Permanent School Fund Corp’s holdings in West Pharmaceutical Services were worth $5,726,000 as of its most recent SEC filing.
Several other large investors have also recently added to or reduced their stakes in WST. Norges Bank bought a new stake in shares of West Pharmaceutical Services during the fourth quarter worth $237,367,000. Artisan Partners Limited Partnership increased its position in West Pharmaceutical Services by 57.2% in the 3rd quarter. Artisan Partners Limited Partnership now owns 1,591,271 shares of the medical instruments supplier’s stock valued at $597,061,000 after acquiring an additional 578,796 shares in the last quarter. Massachusetts Financial Services Co. MA acquired a new stake in West Pharmaceutical Services in the 3rd quarter valued at about $215,011,000. JPMorgan Chase & Co. lifted its position in shares of West Pharmaceutical Services by 73.2% during the first quarter. JPMorgan Chase & Co. now owns 849,266 shares of the medical instruments supplier’s stock worth $294,246,000 after purchasing an additional 359,021 shares in the last quarter. Finally, Bank of Montreal Can bought a new stake in shares of West Pharmaceutical Services during the second quarter valued at approximately $73,389,000. 91.23% of the stock is owned by institutional investors.
West Pharmaceutical Services Price Performance
West Pharmaceutical Services stock opened at $409.64 on Monday. The firm has a market capitalization of $30.31 billion, a P/E ratio of 55.28, a PEG ratio of 4.04 and a beta of 1.05. The business has a 50-day moving average of $358.15 and a 200-day moving average of $367.59. The company has a current ratio of 3.70, a quick ratio of 2.89 and a debt-to-equity ratio of 0.05. West Pharmaceutical Services, Inc. has a 1 year low of $264.52 and a 1 year high of $415.73.
West Pharmaceutical Services Dividend Announcement
Wall Street Analyst Weigh In
Several research analysts recently weighed in on the stock. Jefferies Financial Group upgraded shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $323.00 to $536.00 in a research report on Wednesday, February 7th. StockNews.com upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research report on Thursday, December 7th. Finally, Stephens decreased their price target on West Pharmaceutical Services from $420.00 to $390.00 and set an “overweight” rating on the stock in a report on Friday, October 27th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $412.20.
Insider Buying and Selling
In other news, CAO Chad Winters sold 1,013 shares of the business’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $349.00, for a total value of $353,537.00. Following the sale, the chief accounting officer now directly owns 1,270 shares in the company, valued at $443,230. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 1.13% of the stock is owned by company insiders.
West Pharmaceutical Services Profile
West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
- Five stocks we like better than West Pharmaceutical Services
- Options Trading – Understanding Strike Price
- Uber quadruples EPS estimates, but is growth decelerating?
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- 3 stocks set to benefit from record Valentine’s Day spending
- P/E Ratio Calculation: How to Assess Stocks
- Tradeweb is a disruptive pure play on financial market liquidity
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.